摘要
目的 探讨13 1I标记物介入治疗原发性肝癌的临床价值。方法 复习相关文献 ,并作综述性报道。结果13 1I 碘化油 (13 1I LPD)及13 1I免疫生物制剂均能较好地聚集于肝癌组织 ,适应证较广 ,严重的不良反应少见 ,近期疗效肯定 ,部分临床试验证实治疗后患者的生存率有提高。结论 运用13
Objective To discuss the clinical val ue of internal radiation therapy with hepatic intra-arterial iodine-131 labele d material for the treatment of hepatocellular carcinoma (HCC). Methods This summarized paper was made on literatu re review. Results Iodine-131-lipiodol and several reported iodine-131-labeled antibodies to HCC associated antigens were concentrated in the foci of HCC with a high tumor-to-normal-tissue absorbed dose ratios. No s evere side effects occurred. It was used in various kinds of HCC patients, and m ostly showed a significant tumor response. Survival rate of HCC patients was rai sed in several clinical trials.Conclusion Internal radiotherapy with hepatic intr a-arterial iodine-131 labeled material may be considered as an effective metho d to treat HCC.
出处
《中国普外基础与临床杂志》
CAS
2003年第5期513-515,共3页
Chinese Journal of Bases and Clinics In General Surgery